Table 1 Clinicopathological characteristics of overall and BRAF inhibitor treated patients
Characteristics | Overall | BRAF inhibitor treated | ||
|---|---|---|---|---|
N | (%) | N | (%) | |
Patients | 64 | (100) | 33 | (100) |
Sex | ||||
Male | 35 | (54.7) | 17 | (51.5) |
Female | 29 | (45.3) | 16 | (48.5) |
Age | ||||
Median (range) | 61 (22–82) | ─ | 53 (22–82) | ─ |
Site of primary melanoma | ||||
Skin | 54 | (84.4) | 29 | (87.9) |
Unknown | 8 | (12.5) | 4 | (12.1) |
Uveal | 2 | (3.1) | 0 | (0) |
Stage at diagnosis | ||||
I | 1 | (1.6) | 1 | (3.1) |
II | 19 | (30.1) | 8 | (24.2) |
III | 26 | (41.3) | 14 | (42.4) |
IV | 17 | (27) | 10 | (30.3) |
Metastatic stage | ||||
M1a | 13 | (20.3) | 7 | (21.2) |
M1b | 9 | (14.1) | 6 | (18.2) |
M1c | 42 | (65.6) | 20 | (60.6) |
Brain metastasis | ||||
No | 41 | (64.1) | 23 | (69.7) |
Yes | 23 | (35.9) | 10 | (30.3) |
N° metastasis | ||||
≤ 2 | 28 | (43.7) | 13 | (39.4) |
> 2 | 36 | (56.3) | 20 | (60.6) |
DFS | ||||
Median (range) | 12 (0–144) | ─ | 12 (0–136) | ─ |
OS | ||||
Median (range) | 32 (2–182) | ─ | 31.5 (5–145) | ─ |
OSMD | ||||
Median (range) | 12.5 (2–86) | ─ | 14 (4–54) | ─ |